MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):997-1003. doi: 10.15585/mmwr.mm7028e1.
On May 10, 2021, the Food and Drug Administration (FDA) expanded its Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12-15 years; this authorization was followed by interim recommendations from the Advisory Committee on Immunization Practices (ACIP) for the vaccine among this age group (1). Using data from nonprobability-based Internet panel surveys administered by the Healthcare and Public Perceptions of Immunizations (HaPPI) Survey Collaborative, the acceptability of adolescent COVID-19 vaccination and self-reported factors increasing vaccination intent were assessed among independently recruited samples of 985 adolescents aged 13-17 years and 1,022 parents and guardians (parents) of adolescents aged 12-17 years during April 15-April 23, 2021, prior to vaccine authorization for this age group. Approximately one quarter (27.6%) of parents whose adolescents were already vaccine-eligible (i.e., aged 16-17 years) reported their adolescent had received ≥1 COVID-19 vaccine dose, similar to the proportion reported by vaccine-eligible adolescents aged 16-17 years (26.1%). However, vaccine receipt reported by parents of adolescents differed across demographic groups; parents identifying as female or Hispanic, or who had an education lower than a bachelor's degree reported the lowest adolescent COVID-19 vaccination receipt. Among parents of unvaccinated adolescents aged 12-17 years, 55.5% reported they would "definitely" or "probably" have their adolescent receive a COVID-19 vaccination. Among unvaccinated adolescents aged 13-17 years, 51.7% reported they would "definitely" or "probably" receive a COVID-19 vaccination. Obtaining more information about adolescent COVID-19 vaccine safety and efficacy, as well as school COVID-19 vaccination requirements, were the most commonly reported factors that would increase vaccination intentions among both parents and adolescents. Federal, state, and local health officials and primary care professionals were the most trusted sources of COVID-19 vaccine information among both groups. Efforts focusing on clearly communicating to the public the benefits and safety of COVID-19 vaccination for adolescents, particularly by health care professionals, could help increase confidence in adolescent COVID-19 vaccine and vaccination coverage.
2021 年 5 月 10 日,美国食品和药物管理局(FDA)扩大了辉瑞-生物科技公司 COVID-19 疫苗的紧急使用授权范围,将其纳入 12-15 岁的青少年;随后,免疫实践咨询委员会(ACIP)提出了该年龄段青少年接种疫苗的临时建议(1)。利用非概率性互联网小组调查数据,由医疗保健和公众对免疫接种的看法(HaPPI)调查合作组织管理,在 2021 年 4 月 15 日至 4 月 23 日期间,对独立招募的 985 名 13-17 岁青少年和 1022 名 12-17 岁青少年的父母或监护人(父母)进行了 COVID-19 疫苗接种的可接受性和自我报告的增加疫苗接种意愿的因素评估。在已经有资格接种疫苗的青少年(即 16-17 岁)中,约四分之一(27.6%)的父母报告其青少年已接种至少 1 剂 COVID-19 疫苗,与报告已接种 16-17 岁青少年的比例相似17 岁)。然而,父母报告的青少年疫苗接种情况因人口统计学群体而异;自认为是女性或西班牙裔,或受教育程度低于学士学位的父母报告青少年 COVID-19 疫苗接种率最低。在未接种疫苗的 12-17 岁青少年的父母中,55.5%表示他们“肯定”或“可能”会让青少年接种 COVID-19 疫苗。在未接种疫苗的 13-17 岁青少年中,51.7%表示他们“肯定”或“可能”会接种 COVID-19 疫苗。了解更多关于青少年 COVID-19 疫苗安全性和有效性的信息,以及学校 COVID-19 疫苗接种要求,是父母和青少年增加疫苗接种意愿的最常见报告因素。联邦、州和地方卫生官员以及初级保健专业人员是这两个群体中最信任的 COVID-19 疫苗信息来源。通过卫生保健专业人员等,重点向公众清楚地传达 COVID-19 疫苗对青少年的益处和安全性,这可能有助于提高青少年对 COVID-19 疫苗和疫苗接种覆盖率的信心。